Evaluation of Subcutaneous Implantable Cardiac Defibrillator in Brugada Patients

Inclusion Criteria: \- Patient with type I Brugada syndrome eligible for implantation of an S-ICD system: Symptomatic : (history of resuscitated sudden death, syncope) with an ECG showing an aspect of Brugada syndrome type I before or after pharmacological tests (ajmaline or flecainide test) according to the criteria of the consensus conference and after ECG validation by the Clinical Events Committee experts. Asymptomatic: with an aspect of spontaneous type I Brugada syndrome after ECG validation by the Clinical Events Committee experts. * Brugada syndrome patient with Indication for ICD replacement. * No contra-indication for S-ICD implantation (anatomic or physiologic criteria) with particular attention to the validation of the ECG prescreening implantation. For this study at least 2 vectors must be suitable for S-ICD implantation. * Patients whose age is 18 years or above, or of legal age to give informed consent specific to state and national law. * Patients who are willing and capable of providing informed consent, participating in all testing associated with this clinical investigation at an approved clinical investigational center. Exclusion Criteria: * Incessant ventricular tachycardia (VT) and/or documented spontaneous, frequently recurring VT that is reliably terminated with anti-tachycardia pacing. * Patients with unipolar pacemakers or implanted devices that revert to unipolar pacing. * Presence of any severe medical condition such that the patient is not expected to survive for the planned study follow-up period. * Minor, patient under trusteeship or under guardianship. * Patients who currently participate in an investigational drug or device that clinically interferes with the S-ICD-Brugada registry study endpoints and results. * Female of childbearing potential without adequate contraception at the time of the implantation. * Inability to comply with the follow-up schedule.